Actuate Therapeutics, Inc. Common stock
Symbol: ACTU (NASDAQ)
7.12
▼ (-16.35%) -1.391
Company Description:
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Key Stats
- Today's Open: $6.4
- Today's High: $7.98
- Today's Low: $6.355
- Today's Volume: 482.92K
- Yesterday Close: $8.51
- Yesterday High: $8.55
- Yesterday Low: $7.64
- Yesterday Volume: 44.27K
- Last Min Volume: 0
- Last Min High: $7.119
- Last Min Low: $6.82
- Last Min VWAP: $0
Company Profile
- Name: Actuate Therapeutics, Inc. Common stock
- Website: https://www.actuatetherapeutics.com
- Listed Date: 2024-08-13
- Location: FORT WORTH, TX
- Market Status: Active
- CIK Number: 0001652935
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $164.72M
- Round Lot: 100
- Outstanding Shares: 20.75M
- Asset Type: CS
RECENT FILINGS FOR ACTU
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-10 | 8-K | View |
| 2025-09-10 | 424B5 | View |
| 2025-09-09 | 424B5 | View |
| 2025-09-08 | EFFECT | View |
| 2025-09-02 | S-3 | View |
| 2025-08-18 | DRS | View |
| 2025-08-14 | 10-Q | View |
| 2025-08-04 | EFFECT | View |
| 2025-08-04 | 424B3 | View |
| 2025-07-31 | CORRESP | View |
| 2025-07-31 | UPLOAD | View |
| 2025-07-25 | S-1 | View |
| 2025-07-07 | D | View |
| 2025-06-30 | 4 | View |
| 2025-06-30 | 4 | View |
| 2025-06-30 | 4 | View |
| 2025-06-30 | SCHEDULE 13D/A | View |
| 2025-06-26 | 8-K | View |
| 2025-06-05 | 8-K | View |
| 2025-06-02 | 8-K | View |
Latest News on ACTU